D Il'yasova1, F Wang, R B D'Agostino, A Hanley, L E Wagenknecht. 1. Department of Community and Family Medicine, Prevention Research Division, Duke University Medical Center, Box 2949, Durham, NC, 27710, USA, dora.ilyasova@duke.edu.
Abstract
AIMS/HYPOTHESIS: Elevated fasting NEFAs are thought to promote type 2 diabetes. Three prospective studies support this concept, showing increased diabetes risk associated with fasting NEFA. However, these prospective associations may be confounded by strong cross-sectional correlations between fasting NEFA and metabolic predictors of diabetes. To examine this assumption, we used cohort data from the Insulin Resistance Atherosclerosis Study (IRAS). METHODS: Within the IRAS cohort (n = 902, 145 incident cases), we examined nine metabolic variables for their confounding effect on the fasting NEFA-diabetes association: 2 h glucose; fasting plasma glucose; body mass index; waist circumference; waist-to-hip ratio; weight; insulin sensitivity (S (I)); fasting insulin; and acute insulin response. We compared odds ratios for fasting NEFA (log( e ) transformed and adjusted for age, sex, ethnicity and clinic) before and after inclusion of each metabolic variable into a logistic regression model. RESULTS: Three variables (2 h glucose, BMI and S (I)) cross-sectionally correlated with fasting NEFA (r > or = 0.1, p < 0.05). Unadjusted for metabolic predictors, fasting NEFA levels were positively associated with diabetes risk: OR 1.37 (95% CI 0.87-2.15) per unit on a log scale. All metabolic variables except AIR showed confounding. Inclusion of 2 h glucose reversed the positive association (OR 0.50 [95% CI 0.30-0.82]), whereas other predictors reduced the association to the null. The final model included the variables correlated with baseline fasting NEFA (2 h glucose, BMI and S (I)) and the demographic variables resulting in OR 0.47 (95% CI 0.27-0.81). CONCLUSIONS/ INTERPRETATION: Our results indicate that 2 h glucose strongly confounds the prospective association between fasting NEFA and diabetes; carefully adjusted fasting NEFA levels are inversely associated with diabetes risk.
AIMS/HYPOTHESIS: Elevated fasting NEFAs are thought to promote type 2 diabetes. Three prospective studies support this concept, showing increased diabetes risk associated with fasting NEFA. However, these prospective associations may be confounded by strong cross-sectional correlations between fasting NEFA and metabolic predictors of diabetes. To examine this assumption, we used cohort data from the Insulin Resistance Atherosclerosis Study (IRAS). METHODS: Within the IRAS cohort (n = 902, 145 incident cases), we examined nine metabolic variables for their confounding effect on the fasting NEFA-diabetes association: 2 h glucose; fasting plasma glucose; body mass index; waist circumference; waist-to-hip ratio; weight; insulin sensitivity (S (I)); fasting insulin; and acute insulin response. We compared odds ratios for fasting NEFA (log( e ) transformed and adjusted for age, sex, ethnicity and clinic) before and after inclusion of each metabolic variable into a logistic regression model. RESULTS: Three variables (2 h glucose, BMI and S (I)) cross-sectionally correlated with fasting NEFA (r > or = 0.1, p < 0.05). Unadjusted for metabolic predictors, fasting NEFA levels were positively associated with diabetes risk: OR 1.37 (95% CI 0.87-2.15) per unit on a log scale. All metabolic variables except AIR showed confounding. Inclusion of 2 h glucose reversed the positive association (OR 0.50 [95% CI 0.30-0.82]), whereas other predictors reduced the association to the null. The final model included the variables correlated with baseline fasting NEFA (2 h glucose, BMI and S (I)) and the demographic variables resulting in OR 0.47 (95% CI 0.27-0.81). CONCLUSIONS/ INTERPRETATION: Our results indicate that 2 h glucose strongly confounds the prospective association between fasting NEFA and diabetes; carefully adjusted fasting NEFA levels are inversely associated with diabetes risk.
Authors: M A Charles; E Eschwège; N Thibult; J R Claude; J M Warnet; G E Rosselin; J Girard; B Balkau Journal: Diabetologia Date: 1997-09 Impact factor: 10.122
Authors: G Lattuada; F Costantino; A Caumo; P Scifo; F Ragogna; F De Cobelli; A Del Maschio; L Luzi; G Perseghin Journal: Diabetologia Date: 2005-03-10 Impact factor: 10.122
Authors: Dora Il'yasova; Ivan Spasojevic; Karel Base; Haoyue Zhang; Frances Wang; Sarah P Young; David S Millington; Ralph B D'Agostino; Lynne E Wagenknecht Journal: Diabetes Care Date: 2011-11-18 Impact factor: 19.112
Authors: Marina Fugmann; Olaf Uhl; Christian Hellmuth; Holger Hetterich; Nora N Kammer; Uta Ferrari; Klaus G Parhofer; Berthold Koletzko; Jochen Seissler; Andreas Lechner Journal: PLoS One Date: 2015-05-26 Impact factor: 3.240
Authors: Dora Il'yasova; Lynne E Wagenknecht; Ivan Spasojevic; Steven Watkins; Donald Bowden; Frances Wang; Ralph B D'Agostino Journal: Oxid Med Cell Longev Date: 2015-02-23 Impact factor: 6.543
Authors: Flavia De Conti Cartolano; Caroline Pappiani; Maria Camila Prupper de Freitas; Antonio M Figueiredo Neto; Antônio Augusto Ferreira Carioca; Nágila Raquel Teixeira Damasceno Journal: Arq Bras Cardiol Date: 2018-04 Impact factor: 2.000
Authors: Luc Djoussé; Owais Khawaja; Traci M Bartz; Mary L Biggs; Joachim H Ix; Susan J Zieman; Jorge R Kizer; Russell P Tracy; David S Siscovick; Kenneth J Mukamal Journal: Diabetes Care Date: 2012-05-14 Impact factor: 19.112